Organogenesis (NASDAQ:ORGO) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Organogenesis (NASDAQ:ORGOGet Rating) released its quarterly earnings data on Tuesday. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.04), MarketWatch Earnings reports. Organogenesis had a return on equity of 50.66% and a net margin of 20.28%. During the same quarter in the prior year, the company earned $0.07 earnings per share. Organogenesis updated its FY 2022 guidance to EPS.

Shares of Organogenesis stock traded up $0.64 on Wednesday, hitting $6.17. 58,937 shares of the company traded hands, compared to its average volume of 1,029,499. The firm’s 50-day simple moving average is $7.43 and its 200 day simple moving average is $8.49. The company has a current ratio of 2.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.29. The company has a market cap of $796.39 million, a P/E ratio of 8.86 and a beta of 1.72. Organogenesis has a 12-month low of $5.30 and a 12-month high of $19.75.

Separately, Zacks Investment Research cut shares of Organogenesis from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 8th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $19.75.

In other news, VP Antonio S. Montecalvo sold 97,436 shares of the firm’s stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $8.39, for a total transaction of $817,488.04. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 34.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of ORGO. Royal Bank of Canada raised its position in shares of Organogenesis by 25.9% during the 2nd quarter. Royal Bank of Canada now owns 4,179 shares of the company’s stock valued at $69,000 after buying an additional 861 shares in the last quarter. ProShare Advisors LLC raised its position in Organogenesis by 47.6% in the 1st quarter. ProShare Advisors LLC now owns 15,211 shares of the company’s stock worth $117,000 after purchasing an additional 4,905 shares during the period. Guggenheim Capital LLC purchased a new position in Organogenesis in the 4th quarter worth $250,000. Cubist Systematic Strategies LLC raised its position in Organogenesis by 92.3% in the 4th quarter. Cubist Systematic Strategies LLC now owns 35,665 shares of the company’s stock worth $330,000 after purchasing an additional 17,114 shares during the period. Finally, State of Tennessee Treasury Department raised its position in Organogenesis by 14.5% in the 4th quarter. State of Tennessee Treasury Department now owns 36,149 shares of the company’s stock worth $334,000 after purchasing an additional 4,570 shares during the period. Hedge funds and other institutional investors own 38.41% of the company’s stock.

About Organogenesis (Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Recommended Stories

Earnings History for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.